Main study parameter/endpoints
breasts
CAVITY
The main study end point is breast volume change over the duration of this study. For this purpose, 3D breast images and breast-chest circumference differences are measured (centimeters). 3D imaging of the breasts is carried out using an Artec Leo 3D (Artec 3D, Luxembourg, Luxembourg) scanner in order to determine breast volume. The Artec LEO is a wireless vertical cavity surface-emitting laser scanner (VCSEL) and an improved and more accurate version of the Artec Eva 3D scanner. Previous research has shown that the Artec Eva 3D scanner provides accurate, valid and reliable 3D scans [After inclusion, we obtain a complete history (including current or previous illnesses, medication, smoking, alcohol use, family history, previous use of progesterone and cyproterone acetate). At baseline and during follow-up, the following patient characteristics will be recorded: age, height, weight, BMI, blood pressure, alcohol use, smoking, type of estradiol use and breast volume. At the start of the study and after six and twelve months, venous blood samples are obtained and analyzed for determination of concentrations of 17-beta-estradiol, progesterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, sex hormone-binding globulin (SHBG), as well as alkaline phosphatase (APH), gamma-glutamyltransferase (gamma-GT), alanine-aminotransferase (ALAT) and aspartate-aminotransferase (ASAT), low-density lipoprotein (LDL) and HDL cholesterol and triglyceride levels. Estradiol concentrations will be measured using liquid chromatography followed by mass spectrometry. Progesterone, LH, FSH, prolactin and SBHG will be measured using immunoassays.Satisfaction is assessed at the start of the intervention and during the follow-up visits by three online questionnaires: the Rosenberg self-esteem scale [